Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | FFAR3 | O14843 | 2/20 | 0.32 |
| ▸ | PPARA | Q07869 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | MME | P08473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28460328 | 0.85 | CYP2C19 (0.32) | CYP2C19 | |
| SCHEMBL23094032 | 0.84 | GPR84 (0.38) | — | |
| SCHEMBL9972635 | 0.83 | CYP2C19 (0.30) | CYP2C19 | |
| SCHEMBL17507162 | 0.81 | CYP2C19 (0.38) | CYP2C19TSHRUSP2ALDH1A1LMNA | |
| SCHEMBL5667980 | 0.79 | SLC6A4 (0.39) | CYP2C19TSHRUSP2ALDH1A1LMNA | |
| SCHEMBL14037320 | 0.78 | CYP2C19 (0.34) | CYP2C19TSHRFFAR3MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL5665595 | 0.78 | SLC6A4 (0.38) | CYP2C19TSHRUSP2ALDH1A1LMNA | |
| SCHEMBL14576719 | 0.77 | CA2 (0.36) | CYP2C19MEN1KMT2AMME | |
| SCHEMBL1469950 | 0.77 | CHRM1 (0.38) | CYP2C19TSHRUSP2ALDH1A1LMNA | |
| SCHEMBL3664521 | 0.77 | SLC6A4 (0.36) | CYP2C19TSHRUSP2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8664403-B2 | Process | HOFFMANN-LA ROCHE INC. (US) | 2014-03-04 | — | — | US | disclosed |
| US-8664403-B2 | Process | HOFFMANN-LA ROCHE INC. (US) | 2014-03-04 | — | — | US | disclosed |
| US-20120157504-A1 | New Process | HOFFMANN-LA ROCHE INC. | 2012-06-21 | — | — | US | disclosed |
| US-20120157504-A1 | New Process | HOFFMANN-LA ROCHE INC. | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157504-A1 | New Process | CYP3A4, TPMT, CYP4B1 | CYP2C19 95/4885TSHR 3102/4885USP2 2313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.